Timing of diverting ileostomy closure after low anterior resection for rectal cancer: a GRADE-assessed systematic review and meta-analysis of early and delayed closure.

Langenbecks Arch SurgOct 24, 2026 (epub)
Clinical ResearchGeneral SurgeryOncology (Medical)Open access

Wajahat Mirza, Sana Ehsan Ullah, Muhammad Babar et al.

✦ AI-curated · Sources linked

In 30 seconds

This GRADE-assessed systematic review and meta-analysis compared early with delayed diverting ileostomy closure after low anterior resection for rectal cancer. It included five comparative studies—four randomised trials and one prospective cohort—with 512 participants. Overall post-closure morbidity was reported in 52/257 patients after early closure and 50/255 after delayed closure (RR 1.06, 95% CI 0.66-1.71). The analysis found no statistically significant difference in morbidity, severe complications, reoperation, hospital stay, or operative time; the evidence does not establish that the approaches are equivalent.

Key findings

  • Overall morbidity occurred in 52/257 patients after early closure and 50/255 after delayed closure (RR 1.06, 95% CI 0.66-1.71).
  • The index-to-closure interval was 107.09 days shorter with early closure (95% CI - 153.01 to - 61.17; I²=96%).
  • Severe complications and reoperation did not differ statistically; confidence intervals were compatible with benefit or harm.
  • Hospital stay and operative time did not differ statistically between early and delayed closure.

Why it matters

Ileostomy closure timing involves balancing earlier restoration of continuity against postoperative risk. This synthesis found no statistically significant morbidity difference, but its uncertainty means absence of a detected difference should not be interpreted as equivalence. The findings help frame timing as a decision requiring patient selection and assessment rather than a universally established early-closure strategy.

What to keep in mind

Only five comparative studies were included, and the confidence intervals for morbidity and other complications were compatible with benefit or harm. The index-to-closure interval had substantial heterogeneity (I²=96%) and was largely inherent to the group definitions.

Source

Published in Langenbecks Arch Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.